Acorda Therapeutics Profit Margin 2010-2022 | ACOR
Current and historical gross margin, operating margin and net profit margin for Acorda Therapeutics (ACOR) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Acorda Therapeutics net profit margin as of September 30, 2022 is -85.97%.
| Acorda Therapeutics Annual Profit Margins |
| Acorda Therapeutics Quarterly Profit Margins |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.023B |
$0.129B |
|
Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg.
|
